Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
5,741
Total Claims
$2.4M
Drug Cost
568
Beneficiaries
$4,309
Cost/Patient
Risk Score Breakdown 25/100
Score components are additive. Read full methodology
Peer Comparison vs. 13,194 Neurology providers
-23%
Opioid rate vs peers
1.0% vs 1.3% avg
+7%
Cost per patient vs peers
$4,309 vs $4,034 avg
-5%
Brand preference vs peers
9.0% vs 9.4% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
1.0%
Opioid Rate
58
Opioid Claims
$1,098
Opioid Cost
27.6%
Long-Acting Rate
Brand vs Generic
Brand: 514 claims · $2.1M
Generic: 5,213 claims · $326K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Immun Glob G(Igg)/Pro/Iga 0-50 | 22 | $358K |
| Immun Globg(Igg)/Malt/Iga Ov50 | 12 | $262K |
| Immun Glob G(Igg)/Gly/Iga Ov50 | 23 | $218K |
| Rimegepant Sulfate | 83 | $170K |
| Deutetrabenazine | 23 | $149K |
| Immune Globul G/Gly/Iga Avg 46 | 28 | $146K |
| Valbenazine Tosylate | 13 | $110K |
| Ofatumumab | 12 | $106K |
| Ubrogepant | 48 | $74K |
| Erenumab-Aooe | 62 | $55K |
| Tirzepatide | 24 | $34K |
| Onabotulinumtoxina | 13 | $31K |
| Rivastigmine | 74 | $31K |
| Atogepant | 18 | $21K |
| Gabapentin | 886 | $19K |
Prescribing Profile
Patient Profile
75
Avg Age
63%
Female
1.67
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About